MK-0752 Clinical Trials

Size	Price	Qty
5mg	USD 270
50mg	USD 970

Clinical Trials

MK-0752 has been evaluated in multiple Phase 1, Phase 2, and Phase 4 clinical trials involving healthy volunteers and patients with advanced solid tumors, central nervous system malignancies, acute T-cell lymphoblastic leukemia, pancreatic cancer, and metastatic breast cancer. Supported by industry sponsors like Merck Sharp & Dohme LLC alongside academic institutions such as Cancer Research UK and the Pediatric Brain Tumor Consortium, these protocols comprise both completed and terminated studies.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01098344	COMPLETED	Pancreatic Cancer	Cancer Research UK	2010-04	PHASE1
NCT01295632	COMPLETED	Advanced Cancer	Merck Sharp & Dohme LLC	2011-02	PHASE1
NCT01243762	TERMINATED	Neoplasms Malignant	Merck Sharp & Dohme LLC	2010-11-22	PHASE1
NCT00756717	COMPLETED	Breast Cancer	Loyola University	2008-02-14	PHASE4
NCT00106145	COMPLETED	Advanced Breast Cancer; Other Solid Tumors	Merck Sharp & Dohme LLC	2005-04	PHASE1
NCT01295632	Completed	Advanced Cancer	Merck Sharp & Dohme LLC	2011-02	Phase 1
NCT00572182	TERMINATED	Brain and Central Nervous System Tumors	Pediatric Brain Tumor Consortium	2008-07	PHASE1
NCT00645333	COMPLETED	Metastatic Breast Cancer	University of Michigan Rogel Cancer Center	2008-03	PHASE1; PHASE2
NCT00803894	COMPLETED	Healthy	Merck Sharp & Dohme LLC	2008-12	PHASE1
NCT00572182	Terminated	Brain and Central Nervous System Tumors	Pediatric Brain Tumor Consortium\|National Cancer Institute (NCI)	2008-07	Phase 1
NCT00100152	TERMINATED	Leukemia, Lymphoblastic, Acute, T-cell; Myelogenous Leukemia; Chronic Lymphocytic Leukemia; Myelodysplastic Syndromes	Merck Sharp & Dohme LLC	2005-02	PHASE1

(data from https://clinicaltrials.gov, updated on 2015-10-14)

Check the MK-0752 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

MK-0752 selectively binds to and inhibits γ-secretase, thereby blocking the downstream proteolytic cleavage of Notch transmembrane receptors and amyloid precursor protein. This inhibition suppresses oncogenic Notch signaling pathways to attenuate cellular proliferation, which directly provides the rationale for its clinical investigation in solid tumors, pancreatic cancer, and leukemia.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).